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ABSTRACT
Bronchiolitis obliterans (BrOb), a late complication of bone marrow transplantation (BMT), is associated with
chronic graft-versus-host disease (GVHD) and is frequently fatal. To identify the risk factors associated with
BrOb, the factors affecting survival, treatment outcomes, and causes of death of patients with BrOb, we
retrospectively analyzed 2859 BMT recipients. No cases of BrOb occurred among 1070 autologous BMT
recipients. Among 1789 allogeneic BMT recipients, we identified 47 patients with BrOb. In multivariate
analysis, older recipients or donors and acute GVHD were significantly associated with the development of
BrOb. Among patients with BrOb, 5-year survival from the time of transplantation was only 10%, versus 40%
among allogeneic BMT recipients without BrOb. The clinical course of BrOb had a significant effect on
survival: 79% survived 5 years from the time of BrOb diagnosis if BrOb improved versus 13% if there was no
improvement after the first-line therapy. Predictors of response included older donors and recipients, a
previous diagnosis of chronic GVHD, and diagnosis of BrOb 6 months after transplantation; each of these
significantly increased the likelihood of a favorable response to treatment. BrOb had high mortality rate of
55%, and pulmonary failure was the leading cause of death. More effective BrOb therapy is needed, especially
for patients with unfavorable presentation.
© 2003 American Society for Blood and Marrow Transplantation
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Allogeneic bone marrow transplantation (BMT)
as revolutionized the therapeutic approach toward
cute and chronic leukemia, aplastic anemia, and rare
mmunodeﬁciency disorders. Half of all patients who
ndergo BMT achieve long-term disease-free sur-
ival, but a similar number develop signiﬁcant com-
lications. Pulmonary complications remain frequent
ause of posttransplantation mortality [1-4]. With
rolonged survival after BMT, there is an increased
ecognition of the relatively late posttransplantation
yndrome of bronchiolitis obliterans (BrOb).
BrOb, an obstructive pulmonary disease of small
irways after BMT, was ﬁrst described by Roca et al.
5] in 1982 in a patient with chronic graft-versus-host
isease (cGVHD). Since then, several studies have c
B&MTeported a 2% to 20% incidence of BrOb in BMT
atients. Despite the variety of therapeutic protocols,
he mortality of BrOb is very high, ranging from 21%
o 100% [6-13]. With the exception of 3 described
ases of BrOb after autologous BMT [14,15], the
ate-onset posttransplantation obstructive lung disease
rimarily affects allogeneic recipients. It has been as-
ociated with cGVHD, use of methotrexate for
VHD prophylaxis, and hypogammaglobulinemia
7-9].
The pathogenesis of BrOb in BMT recipients has
ot yet been well deﬁned. It has been suggested that
he changes leading to the cicatricial form of BrOb
ay evolve from interstitial pneumonia and BrOb-
rganizing pneumonia (BOOP) [16]. Donor lympho-oi:10.1016/S1083-8791(03)00242-8r
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the graft-versus-host reaction in an animal model [17].
The onset of BrOb is often insidious. It may start
without initial respiratory symptoms, with normal-
appearing or hyperinﬂated lungs on chest radiograms,
and thus the disease is difﬁcult to diagnose and treat at
an early stage. Furthermore, the variable clinical
course of BrOb [8] may suggest the existence of yet-
unknown factors involved in its pathophysiology. Dif-
ferences in reported outcomes may be due to the
inclusion of BOOP in some series, a distinctly differ-
ent disease entity with a usually favorable response to
steroid therapy [18-21].
In this study, we retrospectively analyzed 2859
BMT recipients to determine risk factors for BrOb,
factors affecting survival, treatment outcomes after
different therapeutic regimens, and causes of death for
patients diagnosed with BrOb.
METHODS
Study Population
We retrospectively analyzed 2859 patients who
received BMT at the University of Minnesota be-
tween January 1, 1980, and January 31, 1999. The
database was searched for patients with a diagnosis of
BrOb, BOOP, pulmonary GVHD, or interstitial
pneumonitis, and when patients were found, their
database records were reviewed in detail. Patients with
an identiﬁed infectious cause of pulmonary disease,
conﬁrmed diagnosis of BOOP, or interstitial pneumo-
nitis without features of pulmonary GVHD were ex-
cluded from further review, leaving 68 cases with a
possible diagnosis of BrOb. All medical records and
available histopathologic materials were further re-
viewed to conﬁrm this diagnosis. Twenty-one patients
were excluded from further analysis because they did
not have pathologic proof of disease and did not meet
criteria for clinical diagnosis, and 47 patients with a
conﬁrmed diagnosis of BrOb were then evaluated.
The diagnosis of BrOb was determined by either his-
topathologic (n  39) or clinical (n  8) evidence.
These patients represent conﬁrmed although possibly
incomplete, case ascertainment.
Histopathologic criteria for BrOb were used in
accordance with previously published morphologic
standards [9] and included obliteration of the airway
lumen of terminal bronchioles due to granulation tis-
sue containing peribronchial, bronchial, and perivas-
cular mononuclear inﬁltrates (Figure 1). Lymphocytic
bronchiolitis—characterized by lymphocytic suben-
dothelial, epithelial, and submucosal inﬁltration with
frequent single-cell necrosis—was included in our
study and categorized as a variant of lung GVHD.
Other lung injuries identiﬁed in conjunction with
GVHD [22], such as diffuse alveolar damage and in-
terstitial pneumonitis, were included in study only if
they were accompanied by changes typical of BrOb.
Histopathologic diagnosis of BrOb was made in 39
patients: 34 by open lung biopsy, 4 by transbronchial
lung biopsy, and 1 at autopsy.
Clinical diagnosis of BrOb was deﬁned by moder-
ate to severe obstructive ventilatory defects: forced
expiratory volume in 1 second (FEV1) 70% and
FEV1/forced vital capacity 80% of the predicted
value [7,8] along with typical changes on high-resolu-
tion computed tomography. These included areas of
decreased attenuation of lung parenchyma, expiratory
air trapping, and subsegmental or segmental bronchial
Figure 1. Lymphocytic bronchiolitis (A) and partial (B) and total (C) obliteration of bronchioles in BrOb.
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dilatation [23,24]. A clinical diagnosis also required
exclusion of infectious causes recognized on extensive
microbiologic and virologic tests of alveolar lavage
and biopsy specimens. Eight patients were diagnosed
with BrOb on the basis of clinical evidence.
The diagnosis of cGVHD was made by using
published criteria for clinical signs and symptoms and
by histopathologic examination of skin [25], oral mu-
cosa [26], esophageal, liver [27,28], and bronchial and
open lung biopsy samples [29]. Pretransplantation and
posttransplantation details of all patients included in
the study were retrieved from the University of Min-
nesota Blood and Marrow Transplant Database,
which contains prospectively collected extensive clin-
ical data on all patients who have undergone trans-
plantation at our center.
Statistical Analysis
To determine risk factors associated with the
development of BrOb, the following characteristics
were considered in univariate and multiple regres-
sion analyses: recipient and donor age, donor and
recipient sex, sex mismatch, disease treated with
transplants, related or unrelated donor, HLA
match, type of preparative regimen, acute GVHD,
source of stem cells, year of transplantation, GVHD
prophylaxis, and cytomegalovirus (CMV) serosta-
tus. We could not include cGVHD as a risk factor,
because BrOb, considered to be a pulmonary man-
ifestation of cGVHD, was an end point of this
analysis. The cumulative incidence of BrOb was
calculated by treating death from other causes as a
competing risk. Univariate comparisons were per-
formed by using the Mantel-Cox log-rank test sta-
tistic. To evaluate the independent effects of poten-
tial risk factors, forward stepwise regression was
performed with factors retained in the model if P
.1 [30,31]. Nonbaseline factors, such as acute
GVHD and cGVHD, were treated as time depen-
dent.
Clinical improvement (response) was deﬁned by a
10% improvement in FEV1 and a sustained reduction
in the symptoms of shortness of breath and cough
reported to physicians. The following variables were
considered as factors potentially modifying the fre-
quency of response: age of donor and recipient, re-
lated or unrelated transplant, source of stem cells,
prior acute GVHD, prior cGVHD, duration of prior
cGVHD, time from transplantation, severity of lung
damage assessed by pulmonary function test (PFT);
and clinical versus pathologic diagnosis.
Survival was estimated by the Kaplan-Meier
method [32]. The survival of patients diagnosed with
BrOb was compared with the survival of BMT recip-
ients who did not develop BrOb and with the survival
of BMT recipients with GVHD, treating the devel-
opment of BrOb as a time-dependent variable [33].
The inﬂuence on survival of patient demographics,
severity of lung damage as assessed by PFT, clinical
parameters of BrOb, regimens used to treat BrOb,
levels of immunoglobulin, and course of BrOb after
therapy was determined by the log-rank test. Cox
regression was used to examine the independent ef-
fects of these variables on survival.
RESULTS
Prevalence of BrOb after Allogeneic BMT at the
University of Minnesota
Between 1980 and 1999, 2859 patients underwent
BMT (median age, 24.7 years; range, 0.1-67.4 years;
male, n  1628; female, n  1231). A total of 1789
patients were allogeneic recipients, and 1070 were
autologous recipients. Forty-seven of 1789 allogeneic
recipients, but none of the autologous recipients, de-
veloped BrOb. Twenty-nine BrOb patients were
males, and 18 were females (median age, 26.9 years;
range, 4-50.1 years). The median time from transplan-
tation to the onset of BrOb was 465 days (range,
77-3212 days). Of 47 BrOb patients, 38 were already
diagnosed with cGVHD before the onset of BrOb.
The cumulative incidence of BrOb among allogeneic
BMT patients was 2% at 1 year and 3% (95% conﬁ-
dence interval, 2%-4%) at 3 years after transplanta-
tion. Among those with cGVHD, the incidence of
BrOb was 6% at 1 year and 7% (5%-9%) at 3 years
after transplantation (Figure 2).
Risk Factors for BrOb
In the univariate analysis, BrOb was found to be
more frequent in older patients and in recipients with
older donors (Table 1). The 3-year incidence of BrOb
was 0.4% for 0- to 9-year-old recipients, 5% for 10- to
19-year-old recipients, and 3% for recipients 20
years of age (P  .01). Similarly, the 3-year incidence
was 0.4% if donors were 0 to 9 years old, 4% if 10 to
19 years old, and 3% if 20 years of age (P  .01).
Figure 2. Incidence of bronchiolitis obliterans in recipients of
allogeneic transplantation and in patients with GVHD.
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Transplantations performed for nonmalignant dis-
eases (eg, aplastic or Fanconi anemia) resulted in a 1%
BrOb 3-year incidence, 2% for acute leukemia, 5%
for chronic myelogenous leukemia, 1% for myelodys-
plastic syndrome, and 2% if performed for other ma-
lignancies (eg, non-Hodgkin lymphoma; P  .02).
Patients with acute GVHD had 4% 3-year incidence
of BrOb versus those with no history of acute GVHD
Table 1. Incidence of Bronchiolitis Obliterans after Bone Marrow Transplantation
Variable
No. of Cases
3-y Incidence of
BrOb (95% CI)
P
ValueTotal With BrOb
All allogeneic BMT recipients 1789 44 3% (2%-4%)
Patients with chronic GVHD 536 38 7% (5%-9%)
Recipient’s age at the time of BMT (y)
0-9 571 2 0.4% (0%-1%)
10-19 331 16 5% (3%-7%) <.01
20-29 887 26 3% (2%-4%)
Donor’s age at the time of BMT (y)
0-9 269 1 0.4% (0%-1%)
10-19 200 7 4% (2%-6%) .01
>20 1233 33 3% (2%-4%)
Donor and recipient sex match
Male/male 533 11 2% (1%-3%)
Male/female 474 16 3% (1%-5%) NS
Female/male 371 9 2% (0%-4%)
Female/female 353 8 2% (0%-4%)
Cord blood 58 0 0%
Disease treated with BMT
Nonmalignant diseases 437 6 1% (0%-2%)
Acute leukemia 703 14 2% (1%-3%)
CML 452 21 5% (3%-7%) .02
MDS 97 1 1% (0%-3%)
Other malignancies 100 2 2% (0%-5%)
Donor and recipient match
Related donor, HLA matched 1069 33 3% (2%-4%)
Related donor, HLA mismatched 93 1 1% (0%-2%)
Unrelated donor, HLA matched 278 6 2% (0%-4%) NS
Unrelated donor, HLA mismatched 290 3 1% (0%-2%)
Cord blood 58 0 0%
Episode of acute GVHD
Yes 1045 37 4% (3%-5%) <.01
No 744 7 1% (0%-2%)
Source of stem cells
Bone marrow 1670 41 3% (2%-4%)
PBSC 61 3 8% (0%-18%) .13
Cord blood 58 0 0%
Year of transplantation
1980-1984 293 7 2% (0%-4%)
1985-1989 415 11 3% (1%-5%)
1990-1994 577 13 2% (1%-3%) NS
1995-1998 504 13 3% (1%-5%)
Conditioning regimen
TBI 1489 36 3% (2%-4%)
Bu/Cy 123 3 2% (1%-3%) NS
Other 177 5 3% (2%-4%)
GVHD prophylaxis
Methotrexate 1262 34 3% (2%-4%)
Cyclosporine 73 1 2% (0%-5%)
T-cell depletion 369 5 1% (0%-2%) .11
Cord blood plus cyclosporine 39 0 0%
Other 46 4 8% (0%-16%)
CMV serostatus
Recipients and donors both negative 565 17 3% (2%-4%)
Recipient negative, donor positive 226 5 2% (0%-4%) NS
Recipient positive 954 22 2% (1%-3%)
CI indicates conﬁdence interval; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; PBCS, peripheral blood stem cells;
TBI, total body irradiation; Bu/Cy, busulfan plus cyclophosphamide; NS, not signiﬁcant.
A. Z. Dudek et al.
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(1% incidence; P  .01). During the study (1980-
1998), there was no difference in the incidence of
BrOb between time periods (Table 1).
Cox regression analysis identiﬁed older donor and
recipient age and prior acute GVHD as statistically
signiﬁcant independent predictors of BrOb (Table 2).
Type of disease treated with BMT, type of donor,
source of stem cells, and CMV serostatus were not
associated with the development of BrOb.
Treatment of BrOb
In 23 of 47 patients, BrOb improved after treat-
ment; in 8 patients, it remained stable for at least 3
months but later worsened; and in 16 cases, BrOb
progressively worsened despite treatment (Table 3).
Six patients were treated with antithymocyte glob-
ulin (15 mg/kg intravenously for 5 days), bolus meth-
ylprednisolone (250 mg/m2 intravenously twice a day
for 5 days and then weekly for 8 weeks at 15 mg/kg),
daily prednisone (60 mg/m2), and cyclosporine (1.5
mg/kg intravenously every 12 hours). Two of these
patients had improvement of BrOb, 1 had stable dis-
ease (for 3 months) and then a later progressive course
despite the addition of thalidomide (initially 50 mg 4
times a day with a further increase up to 800 mg daily),
and 3 had progressive disease.
Twenty-seven patients were treated with weekly
bolus methylprednisolone (for 8 weeks at 15 mg/kg),
prednisone every other day (0.5 mg/kg orally), and
either cyclosporine (6.25 mg/kg every 12 hours orally)
or azathioprine (0.5 mg/kg/d). Fifteen patients (6
treated with azathioprine and 9 with cyclosporine) had
improvement in BrOb; 3 had stable and then progres-
sive disease, and 9 had progressive disease after initial
therapy. Three patients were also given thalidomide; 2
patients responded, 1 with initially progressive dis-
ease, and one continued to have progressive disease
despite the addition of thalidomide.
In the group of 14 patients treated with pred-
nisone (1 mg/kg orally) alone or with cyclosporine or
azathioprine, 6 patients had BrOb improvement, 4
had stable and then later progressive disease, and 4
had progressive disease. One patient in this group also
received thalidomide but continued to have progres-
sive disease.
Factors Predicting Response in BrOb
The extent of pulmonary damage reﬂected by
PFT was not predictive of response (P  .37).
Whereas 55% of BrOb patients who had cGVHD
responded to initial therapy, no patient without prior
cGVHD responded to initial therapy (P  .02). Older
patients or those with older donors had responsive
disease more frequently (P  .01); (Table 4). In addi-
tion, onset of BrOb 6 months after transplantation
was associated with a higher likelihood of response to
therapy (58% versus 17%; P  .01; Figure 3). Eight
patients were diagnosed with BrOb by using clinical
criteria. They had a higher likelihood of response than
patients diagnosed by biopsy (P  .02). Patients with
BrOb who responded to ﬁrst-line therapy had a supe-
rior 5-year survival of 79% versus 13% for those
whose initial therapy failed.
Survival
BrOb was a major factor associated with poor
survival after transplantation. At 5 years, only 10% of
BrOb patients survived, versus 40% of transplant re-
cipients without BrOb (P  .01). Among patients
diagnosed with cGVHD, but without BrOb, the
chance of 5-year survival was 54%, versus only 29%
among those with both cGVHD and BrOb (P  .01;
Table 5). Patients with low immunoglobulin G levels
at the time of BrOb diagnosis had a 35% probability
of survival at 5 years, versus 64% if they had a normal
immunoglobulin G level; however, this difference was
not statistically signiﬁcant. The type of BrOb treat-
ment and the course of BrOb were examined for their
effect on survival in patients with BrOb, but only the
response to initial therapy was critical. The likelihood
of 5-year survival was 79% if BrOb improved after
ﬁrst-line therapy, whereas it was only 13% if BrOb
either was stable or worsened after initial therapy (P
Table 2. Multiple Regression Analysis of Risk Factors for BrOb
Variable Relative Risk (95% CI) P Value
Donor or recipient age (y)
<10* 1.0
10-20 15.3 (3.5-66.2) <.01
>20 9.9 (2.4-42.0) <.01
Acute GVHD
No* 1.0
Yes 2.6 (1.3-4.9) <.01
*Reference pair.
Table 3. Outcome of Patients with BrOb: Response to First-Line Therapy Yields Better Survival
Response to Therapy No. of Patients
No. of Patients
Who Died of BrOb
No. of Patients Who
Died of Infection
Response 23 1 2
Stable and then progressive BrOb 8 1 6
Progressive BrOb 16 10 3
Bronchiolitis Obliterans in BMT Recipients
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.01; Figure 4). The extent of pulmonary damage re-
ﬂected by PFT was not predictive of survival (P 
.28); however, patients with improving lung function
as measured by PFT had a signiﬁcantly better likeli-
hood of 5-year survival (P  .05; Figure 5). We tested
factors inﬂuencing survival among allogeneic patients
with cGVHD by Cox regression analysis. The diag-
nosis of BrOb (relative risk [RR], 2.0; P  .01), older
donor age (RR, 1.1 per decade; P  .03), GVHD
prophylaxis other than T-cell depletion (RR, 2.1; P 
.01), and prior grade II to IV acute GVHD (RR, 1.9;
P  .01) were each found to be independently signif-
icant factors associated with shorter survival.
Causes of Death in Patients with BrOb
Of 47 patients with BrOb, 26 died during the
study. Twelve patients died of progressive lung disease
associated with continuing cGVHD and pulmonary
failure. One patient died of pulmonary hemorrhage
during therapy for progressive multiorgan cGVHD.
Ten patients died of pulmonary infection: 5 fungal (4
Aspergillus species and 1 Candida glabrata), 4 bacterial
(Escherichia coli, Pseudomonas aeruginosa, Staphylococcus
aureus, and other Gram-positive cocci), and 1 viral
(inﬂuenza A). In 9 of the 10 patients who died of
respiratory infection, 9 had progressive BrOb and
were receiving continuing immunosuppression. Three
patients died of nonpulmonary causes: Epstein-Barr
virus—related lymphoproliferative disease, progres-
sive adrenoleukodystrophy, and E. coli meningitis.
DISCUSSION
BrOb, a pathology of terminal bronchioles, can be
seen as an outcome of number of pathologic processes;
rheumatoid arthritis, toxicity of chrysotherapy, inﬂu-
enza virus, and adenovirus type 2 pulmonary infec-
tions in children, as well as lung and bone marrow
transplantation. In the last group, this pathologic pro-
cess can be a form of cGVHD of the lung. The
diagnosis of bronchiolitis obliterans is distinct from
BOOP, an entity that is not associated with GVHD
and is responsive to steroid therapy [18-21].
Previous reports [7,11,17] suggested that cGVHD
is an important risk factor for the onset of BrOb in
BMT patients and that this transplant complication is
seen almost exclusively in recipients of allogeneic stem
cells. Only 2 reports of BrOb in 3 autologous BMT
patients have been published. Similarly, we have noted
no BrOb in patients treated with autologous trans-
plantation at the University of Minnesota. Clark et al.
[8] reported that the incidence of BrOb 1 year after
BMT was 1% in all allogeneic BMT patients and
4.6% in cGVHD patients. Holland et al. [9] reported
that the incidence of BrOb in allogeneic BMT recip-
ients was 2% and that it was 6% in cGVHD patients.
Using stringent case ascertainment, we observed a 2%
Figure 3. Survival after diagnosis of BrOb: late onset yields better
survival.
Table 4. Factors Affecting the Clinical Course of BrOb
Factors Affecting the Clinical Course of BrOb No. of Patients No. of Responders (%) P Value
Chronic GVHD
No 6 0 .02
Yes 41 23 (55)
Time from transplantation to BrOb (mo)
<6 12 2 (17) .01
>6 35 21 (58)
Type of diagnosis
Clinical 8 7 (88) .02
Pathologic 39 16 (40)
Influence of Age on Clinical Course No. of Patients Median Recipient Age (y) P Value
Clinical outcome
Improved 23 33.7 (9.8-49.4)
Not improved 24 16.3 (4-50.1) <.01
Median donor age (y)
Improved 23 34.1 (21.8-50.8)
Not improved 24 23.2 (8.3-49.5) <.01
A. Z. Dudek et al.
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1-year incidence of BrOb in allogeneic BMT recipi-
ents and a 6% incidence in patients already diagnosed
with cGVHD (Figure 2). We recognize that our case
review may be incomplete and may underestimate the
actual BrOb incidence. The median time between
BMT and diagnosis of BrOb was 465 days, and most
patients developed BrOb 200 days after BMT, sim-
ilar to earlier reports [13]. Long follow-up in our
study identiﬁed a very late onset of BrOb in a few
patients; 6 occurred beyond 3 years after BMT.
We noted that older donor and recipient age and
prior acute GVHD were signiﬁcant risk factors asso-
ciated with BrOb. Clark et al. [7] reported that older
age of recipients, male sex, cigarette-smoking history,
lower FEV1/forced vital capacity ratio before trans-
plantation, HLA-nonidentical grafts, cGVHD, and
immunosuppressive therapy with methotrexate were
risk factors associated with airﬂow obstruction in re-
cipients of bone marrow transplants. In that study,
other factors—including underlying disease for BMT,
conditioning regimen, and development of acute
GVHD—were not associated with the airﬂow ob-
struction.
We observed that there was no association of
BrOb development with the conditioning regimen or
the way total body irradiation was delivered. In con-
trast to the Clark study, we found acute GVHD to be
a signiﬁcant risk factor and that sex, HLA mismatch,
and immunosuppressive therapy were not risk factors
for the development of BrOb. Underlying diseases
were independently associated with BrOb onset in
univariate analysis, but not in multivariate analysis. It
is worth noting that previous studies did not associate
the risk factors with the development of BrOb, but,
rather, with airway obstruction measured by PFT.
We have detected that older age of sibling donors
was associated with a higher incidence of BrOb. We
are not aware of any previous analysis that includes the
Figure 4. Survival of bronchiolitis obliterans patients with a clinical
response after ﬁrst-line treatment versus those with stable or pro-
gressive BrOb.
Figure 5. Survival of BrOb patients with improved versus stable or
worsened PFT.
Table 5. Survival of Allogeneic BMT Recipients Diagnosed with BrOb
Variable
No. of Patients
5-y Survival
(95% CI) P ValueTotal Died
Survival of recipients from the day of transplantation
Among all allogeneic BMT recipients
With BrOb diagnosed 48 26 10% (4%-29%) <.01
No BrOb diagnosed 1741 1035 40% (38%-42%)
Among recipients with GVHD
With BrOb diagnosed 38 22 29% (16%-53%) <.01
No BrOb diagnosed 494 242 54% (50%-59%)
Survival of recipients diagnosed with BrOb from the onset of BrOb
PFT status
Responders and stable 15 4 67% (40%-94%) .13
Nonresponders 13 7 46% (19%-73%)
BrOb therapy
ATG 6 4 NE NS
Methylprednisolone 27 13 50% (30%-70%)
Prednisone 14 8 43% (17%-69%)
BrOb course
Improved 23 4 79% (61%-97%) <.01
Progressive disease 24 21 13% (0%-20%)
CI indicates conﬁdence interval; ATG, antithymocyte globulin; NS, not signiﬁcant; NE, not evaluable.
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donor’s age as a risk factor for BrOb after BMT. In the
lung transplant literature, 1 study reported that donor
age was not associated with BrOb [34], whereas an-
other study found this association [35]. The reason
why donor age might be a risk factor is open to
speculation. It is possible that a younger immune
system has enhanced immunologic plasticity, resulting
in less BrOb and less GVHD. Although alloimmune
reaction to the recipient’s lung is the cause of BrOb
development, the source of stem cells, related versus
unrelated donor, HLA mismatch, and different types
of GVHD prophylaxis were not identiﬁed as risk fac-
tors for BrOb.
In our studied population, 58 patients underwent
cord blood transplantation, and none of them devel-
oped BrOb; however, most of these patients were
children who had undergone transplantation recently,
and it is too early to draw any conclusion about
whether the incidence of BrOb in this group of pa-
tients will be different from the incidence in patients
receiving transplants from other stem cell sources.
Holland et al. [9] reported that 6 of 7 patients
diagnosed with BrOb died of pulmonary failure; 2 had
Pseudomonas infection (1 also had CMV), and 1 had
aspergillosis. The others had no evidence of infection,
and BrOb caused the pulmonary failure. Paz et al. [11]
found that 4 of 104 allogeneic BMT recipients devel-
oped BrOb. Two of these patients died of respiratory
failure at days 300 and 360 after BMT. At the end of
the second year after transplantation, the other 2 pa-
tients were still alive, but 1 required continuous ven-
tilator support. Three of the 4 patients had opportu-
nistic infections. In the study by Clark et al. [8],
mortality was 65% in patients with obstructive lung
disease at 3 years after transplantation, a signiﬁcantly
higher value than the 3-year mortality rate of 44% in
a comparison group of 412 concurrent patients with
cGVHD and normal pulmonary function. The me-
dian survival in that study was approximately 2 years
after transplantation. In most of those patients, the
causes of death were respiratory failure without infec-
tion. Although the median survival length and the
chance of survival in patients diagnosed with BrOb are
variable in different studies, development of BrOb has
a major adverse effect on survival and is a frequent
cause of death.
We analyzed the effects of different factors, such
as serum immunoglobulin levels, response to therapy
measured by improvement in PFT, type of BrOb
treatment, and the clinical course of BrOb after treat-
ment, on the 5-year survival. Improvement in the
clinical course of BrOb after ﬁrst-line therapy was
signiﬁcantly associated with a better 5-year survival of
79%, in contrast to only 13% if there was no response
to initial therapy. In addition, we found notably
poorer survival if BrOb occurred within the ﬁrst 6
months after transplantation compared with later-on-
set BrOb. We have included immunoglobulin level in
the survival analysis because hypogammaglobulinemia
has been suggested as a factor associated with poor
survival in transplant patients, and intravenous immu-
noglobulin replacement has been proposed as another
supportive measure in BrOb treatment. In a con-
trolled trial of long-term administration of intrave-
nous immunoglobulin [36], it was shown that this
therapy was associated with lower risk of BrOb. We
observed a trend that older BrOb patients had a higher
likelihood of having low immunoglobulin levels, but
there was no signiﬁcant difference in 5-year survival
between patients with BrOb who had low or normal
serum immunoglobulin G at the time of BrOb diag-
nosis.
There is no standardized approach for the treat-
ment of BrOb in post-BMT transplant patients. In
study by Sanchez et al. [37], long-term allogeneic
bone marrow transplantation survivors affected by ob-
structive airway disease were analyzed for a pulmonary
response to prednisone, cyclosporine, or azathioprine.
No differences in response between immunosuppres-
sion modalities were detected; however, it was noted
that the optimal response occurred in the ﬁrst 6
months of treatment and that prolonged immunosup-
pression may not be warranted. It is plausible that our
study, which required a sustained response to therapy,
underestimated the treatment response rate, because
treatment failure resulted in more frequent visits to
transplant centers and because patients with stable or
improved disease were usually followed up by local
physicians. Patients with BrOb in our institution were
treated with intravenous weekly methylprednisolone,
alternate-day prednisone and cyclosporine, or antithy-
mocyte globulin; boluses of methylprednisolone,
prednisone, and cyclosporine or azathioprine; or pred-
nisone alone. We observed no signiﬁcant difference in
the 5-year survival of patients treated with these 3
different therapies. Lymphocytic bronchiolitis, prob-
ably an earlier and possibly reversible form of BrOb
[38], was detected in 2 patients in our study. It is
interesting to note that both patients improved clini-
cally after initial therapy. A number of other therapies
have been suggested, such as extracorporeal photo-
phoresis, hydroxychloroquine, mycophenylate, and
rapamycin. In our study, 5 patients were treated with
thalidomide, with similar outcomes; 1 patient re-
sponded, 3 had stable disease, and 1 had progressive
disease. We found that thalidomide had no effect on
improving survival in patients with cGVHD [39] and
observed only this limited activity in patients with
BrOb.
Unfortunately, no model of post-BMT BrOb ex-
ists. Airway injury is predominantly immunologic in
BrOb after lung transplantation [40], with increased
levels of T-helper type 1 cytokines (interferon  and
interleukin-2) and CXC chemokines (regulated on
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activation, normal T cells expressed and secreted;
monocytic chemotactic protein-1; and interleukin-8)
[41-45]. It is hypothesized that in cGVHD, endothe-
lial cell injury mediated by cytotoxic T lymphocytes
may underlie processes leading to tissue ﬁbrosis
[46,47]. More selective immune suppression, modula-
tion of chemokine responses [48,49] and protection of
pulmonary endothelium may become a goal of future
therapies to prevent and treat BrOb.
Patients with BrOb and cGVHD who are younger
or have younger donors and a BrOb diagnosis earlier
than 6 months after transplantation have a high like-
lihood of poor response to ﬁrst-line therapy. These
patients should be offered novel treatment strategies
in future studies.
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